Ultragenyx Pharmaceutical Inc. (RARE): Capital Expenditures
$6.00M
Year ended 2025-12-31
-62.8%
3-year compound annual growth
-32.8%
5-year compound annual growth
+1.9%
10-year compound annual growth
| Period ended | Capital Expenditures | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $6.00M | -14.3% | 2026-02-18, From 2025-01-01 |
| 2024-12-31 | $7.00M | -84.1% | 2026-02-18, From 2024-01-01 |
| 2023-12-31 | $44.00M | -62.1% | 2026-02-18, From 2023-01-01 |
| 2022-12-31 | $116.12M | +58.9% | 2025-02-19, From 2022-01-01 |
| 2021-12-31 | $73.09M | +66.5% | 2024-02-21, From 2021-01-01 |
| 2020-12-31 | $43.91M | +76.8% | 2023-02-17, From 2020-01-01 |
| 2019-12-31 | $24.83M | +509.2% | 2022-02-15, From 2019-01-01 |
| 2018-12-31 | $4.08M | +45.9% | 2021-02-12, From 2018-01-01 |
| 2017-12-31 | $2.79M | -72.6% | 2020-02-14, From 2017-01-01 |
| 2016-12-31 | $10.19M | +105.6% | 2019-02-20, From 2016-01-01 |
| 2015-12-31 | $4.96M | +130.6% | 2018-02-21, From 2015-01-01 |
| 2014-12-31 | $2.15M | +428.0% | 2017-02-17, From 2014-01-01 |
| 2013-12-31 | $407.0K | -62.7% | 2016-02-26, From 2013-01-01 |
| 2012-12-31 | $1.09M | n/a | 2015-03-27, From 2012-01-01 |
Capital Expenditures at similar companies
| Company | Year ended | Capital Expenditures | Change YoY |
|---|---|---|---|
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $6.00M | -14.3% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $1.57M | +466.1% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $480.0K | +77.8% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.34M | +84.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $34.88M | -15.0% |
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $15.33M | +44.2% |
| TG Therapeutics, Inc. (TGTX) | 2025-12-31 | $214.0K | +375.6% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $13.80M | -39.7% |
| Opko Health, Inc. (OPK) | 2025-12-31 | $12.28M | -50.9% |
Compare RARE, KNSA, AXSM, SUPN side by side · Screen every company in Pharmaceutical Preparations ↗